Identification of biomarkers that predict severity of COVID-19 patients [Supplement added: Sex as a biological variable supplement, COVID-19 Variant Network]
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 170357, 171495, 175580
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$874,000Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
Canada, China…Lead Research Institution
University of Nova ScotiaResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
Innovation
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The outbreak of the new coronavirus in Wuhan, China has infected over 75,000 people and has caused close to 2,000 deaths. One of the major problems with this outbreak is that emergency rooms, hospitals and ICU wards are overwhelmed with patients. In an effort to find a test for rapidly determining who should be admitted to the hospital and who should be placed in ICU, we have undertaken an international study to find a set of biomarkers that can be used to help Emergency Room doctors to make decisions on whether a patient will become severe. We have established an international team based in China, Vietnam, Spain, Italy, Mozambique, Sudan, Ethiopia, Egypt, Morocco, Cote D' Ivoire and Canada. This team will examine patients peripheral blood for biomarkers that predict the course of disease as mild or severe. The results of the study will be used to make a device that can be used in any situation and rapidly give results to predict the course of coronavirus infections.